Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-Eritadenine is a naturally occurring purine alkaloid found in shiitake mushrooms (Lentinula edodes) and other fungi. It is an adenosine analog and a member of the 6-aminopurines class. D-Eritadenine acts as a potent, reversible inhibitor of S-adenosyl-L-homocysteine hydrolase (SAHH), an enzyme involved in methylation reactions within cells[2][4][5][8]. Through this inhibition, D-eritadenine can disrupt methylation-dependent biological processes. The compound has demonstrated hypocholesterolemic activity in animal studies by altering liver phospholipid metabolism, leading to enhanced removal or reduced release of cholesterol from the liver[5][10]. Its mechanism for lowering cholesterol does not involve direct inhibition of cholesterol biosynthesis but rather modulation of lipid handling by the liver. D-Eritadenine has also shown antiviral properties due to its SAHH inhibitory action[8]. There are no approved pharmaceutical uses for D-eritadenine; it remains primarily an experimental compound studied for its biochemical effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on d-eritadenine.